Preclinical B cell depletion and safety profile of a brain‐shuttled crystallizable fragment‐silenced CD20 antibody

The BBB hinders mAb-based brain disorder therapies A brain-targeted B-cell-depleting mAb for MS that efficiently crosses the BBB via hTfR1 was developed using Brainshuttle^™ technology (1a and 1b) The Brainshuttle^™-CD20 mAb was well tolerated (2a and 2b) and displayed B-cell-killing properties (1c), paving the way for future development and clinical translation of TfR1-targetingtherapies for increased brain penetration.